The estimated Net Worth of Vii Associates Lp Dp is at least 941 千$ dollars as of 1 July 2013. Vii Dp owns over 4,791 units of Zogenix Inc stock worth over 940,550$ and over the last 14 years Vii sold ZGNX stock worth over 0$.
Vii has made over 4 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Vii bought 4,791 units of ZGNX stock worth 67,074$ on 1 July 2013.
The largest trade Vii's ever made was buying 58,696 units of Zogenix Inc stock on 16 September 2011 worth over 117,392$. On average, Vii trades about 19,754 units every 157 days since 2010. As of 1 July 2013 Vii still owns at least 35,253 units of Zogenix Inc stock.
You can see the complete history of Vii Dp stock trades at the bottom of the page.
Vii's mailing address filed with the SEC is C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE, PRINCETON, NJ, 08542.
Over the last 14 years, insiders at Zogenix Inc have traded over 5,100,850$ worth of Zogenix Inc stock and bought 57,764,538 units worth 193,451,745$ . The most active insiders traders include Advisors Llcperceptive Life...、Nicole Vitullo、Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of 13,059,406$. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth 15,000$.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: